MediWound

EscharEx® in VLU

From Phase 2 Evidence to Pivotal Phase 3

April 11, 2026

SAWC Symposium on Advanced Wound Care

Three Phase 2 Studies Show Robust & Consistent Results



1. Shoham et al. 2024; *LANCET's eClinicalMedicine* 2. Snyder et al. 2023; *Wounds* 3. Shoham et al. 2021; *Wound Rep Reg*

Phase 2 MW-EX01 Trial: EscharEx® Effective in Both VLU and DFU



Results[1]

93% of the patients who completed debridement with EscharEx®, achieved full debridement within 7 days (4-5 daily applications)

1. Shoham et al. 2021; *Wound Rep Reg*

Phase 2 ChronEx Trial in VLU: Endpoints Significantly Met

Complete debridement within 2 weeks
(primary endpoint)



EscharEx 63% vs. placebo 30%

Time to wound bed prepared
(complete debridement + healthy granulation tissue)



Median time: EscharEx 11 days vs. placebo 85 days

Results[1] EscharEx Demonstrated to be Safe and Effective

1. Shoham et al. 2024; *LANCET's eClinicalMedicine*

Phase 2 PharmEx Trial: EscharEx® Surpasses Traditional Debridement



Complete debridement achieved within 8 applications
(avg 3.9 applications)



Bioburden reduced by end of treatment



Wound size reduced by end of two-week follow-up

Biofilm substantially reduced for all patients positive for biofilm at baseline

Results[1] Reduction in wound size, biofilm and bacterial burden in VLU and DFU

1. Snyder et al., 2023; *Wounds*

VALUE Phase 3 Trial

STUDY OBJECTIVES

Assess safety and efficacy of EscharEx compared to placebo in VLU patients

STUDY DESIGN

A global (US, EU, ROW), randomized, double blind, adaptive design study in VLU patients

Two arms: EscharEx vs. placebo, 1:1 ratio

Sample size: 216 VLU patients

Study design:

- Up to 8 applications over 2 weeks, followed by 12 weeks of standardized wound management
- Advanced wound closure (Autograft/CTP) for patients reaching wound bed prepared (WBP)
- 3-month patient follow-up

ENDPOINTS

Co-Primary:

Incidence of complete debridement

Facilitation of wound closure, as measured by time to wound closure

1st Co-Primary Endpoint - Incidence of Complete Debridement

ChronEx Phase 2 → **VALUE Phase 3**



Projected outcome



- **Same endpoint**
  Incidence of complete debridement
- **Larger sample size**
  89 → 216
  99% power

2nd Co-primary Endpoint - Time to Wound Closure

ChronEx Phase 2 → **VALUE Phase 3**

Time to wound bed prepared



Median time: EscharEx 11 days vs. placebo 85 days

Projected outcome

- **Favorable endpoint**
  Mandatory active closure, with projected 74-day head start
- **Standardized treatment**
  Throughout study period
- **Larger sample size**
  89 → 216
  >85% power
  Interim analysis for sample size re-assessment